Overview

Bioequivalence Between Albuterol Sulfate Inhalation Aerosol 108mcg Per Actuation and Proair HFA (Albuterol Sulfate) Inhalation Aerosol 90mcg Per Actuation in Healthy Volunteers Under Fasting Conditions

Status:
Active, not recruiting

Trial end date:
2022-05-16

Target enrollment:

Participant gender:

Summary

The objective of this study is to evaluate the bioequivalence between two formulations of MDI, eq. to albuterol 90mcg/puff in healthy volunteers under fasting conditions.

Phase:

N/A

Details

Lead Sponsor:

Intech Biopharm Ltd.

Treatments:

Albuterol